Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Animal venoms are complex mixtures containing peptides and proteins known as toxins, which are responsible for the deleterious effect of envenomations. Across the animal Kingdom, toxin diversity is enormous, and the ability to understand the biochemical mechanisms governing toxicity is not only relevant for the development of better envenomation therapies, but also for exploiting toxin bioactivities for therapeutic or biotechnological purposes. Most of toxinology research has relied on obtaining the toxins from crude venoms; however, some toxins are difficult to obtain because the venomous animal is endangered, does not thrive in captivity, produces only a small amount of venom, is difficult to milk, or only produces low amounts of the toxin of interest. Heterologous expression of toxins enables the production of sufficient amounts to unlock the biotechnological potential of these bioactive proteins. Moreover, heterologous expression ensures homogeneity, avoids cross-contamination with other venom components, and circumvents the use of crude venom. Heterologous expression is also not only restricted to natural toxins, but allows for the design of toxins with special properties or can take advantage of the increasing amount of transcriptomics and genomics data, enabling the expression of dormant toxin genes. The main challenge when producing toxins is obtaining properly folded proteins with a correct disulfide pattern that ensures the activity of the toxin of interest. This review presents the strategies that can be used to express toxins in bacteria, yeast, insect cells, or mammalian cells, as well as synthetic approaches that do not involve cells, such as cell-free biosynthesis and peptide synthesis. This is accompanied by an overview of the main advantages and drawbacks of these different systems for producing toxins, as well as a discussion of the biosafety considerations that need to be made when working with highly bioactive proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 1×
“Some limitations of using venom toxins and peptides as drug leads exist, such as limited membrane permeability and therefore reduced bioavailability for humans, as well as poor in vivo stability and fast clearance (Otvos and Wade, 2014; Lau and Dunn, 2018).”
BackgroundHuman cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Paetzel, M., Karla, A., Strynadka, N. C. J., & Dalbey, R. E. (2002) · Chemical Reviews · doi:10.1021/cr010166y · Cited by 440
Nguyen, V. D., Hatahet, F., Salo, K. E., Enlund, E., Zhang, C., & Ruddock, L. W. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-1 · Cited by 260 · cited 1×
“This is the case for the CyDisCo system (Nguyen et al., 2011; Gaciarz et al., 2016), characterized by the co-expression of two redox enzymes: the mitochondrial oxidase Erv1p from Saccharomyces cerevisiae and human protein-disulfide isomerase (hPDI).”
BackgroundLevy, R., Weiss, R., Chen, G., Iverson, B. L., & Georgiou, G. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1520 · Cited by 207 · cited 1×
“, 2013), and successful expression of correctly folded disulfide-rich peptides can require the co-expression of other chaperones (Levy et al., 2001).”
BackgroundSystematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli
Gaciarz, A., Veijola, J., Uchida, Y., Saaranen, M. J., Wang, C., Hörkkö, S., & Ruddock, L. W. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0419-5 · Cited by 100
Cited by
Rivera‐de‐Torre, E., Lampadariou, S., Møiniche, M., Bohn, M. F., Kazemi, S. M., & Laustsen, A. H. (2024) · Protein Science · doi:10.1002/pro.4901 · Cited by 13
Self-citationOuellet, S., Ferguson, L., Lau, A. Z., & Lim, T. K. Y. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05327-8 · Cited by 5
Ouellet, S., Ferguson, L., Lau, A. Z., & Lim, T. K. Y. (2022) · doi:10.1101/2022.09.17.508377
Metadata
- Authors
- Rivera-de-Torre, E., Rimbault, C., Jenkins, T. P., Sørensen, C. V., Damsbo, A., Saez, N. J., Duhoo, Y., Hackney, C. M., Ellgaard, L., & Laustsen, A. H.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-20
- Volume
- 9
- Pages
- 811905-811905
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W4206581495
- Cited by
- 53
- References
- 6
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins. https://app.cochat.ai/papers/10.3389/fbioe.2021.811905
- The paper
- Rivera-de-Torre, E., Rimbault, C., Jenkins, T. P., Sørensen, C. V., Damsbo, A., Saez, N. J., Duhoo, Y., Hackney, C. M., Ellgaard, L., & Laustsen, A. H. (2022). Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2021.811905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.